Efficacy and safety of novel antipsychotics: a critical review

✍ Scribed by Matteo Balestrieri; Claudio Vampini; Cesario Bellantuono

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 99 KB
• Volume: 15
• Category: Article
• ISSN: 0885-6222
• DOI: 10.1002/1099-1077(200010)15:7<499::aid-hup194>3.0.co;2-3

✦ Synopsis

Efficacy and safety of novel antipsychotic (AP) drugs (amisulpride, olanzapine, quetiapine, ziprasidone and zotepine) have been reviewed. Data on their antipsychotic efficacy and side effects profile have been evaluated only on the basis of controlled trials so far published. Overall, all these drugs have shown an antipsychotic efficacy on positive symptoms of schizophrenia similar to that of the conventional AP drugs. On negative symptoms, all novel AP drugs, except quetiapine and ziprasidone, demonstrated a better efficacy than haloperidol. Long-term efficacy of these AP drugs in the maintenance treatment of schizophrenia needs to be explored by further, better-designed, epidemiological studies. The safety profile shows that the novel AP drugs are generally well-tolerated and induce significantly less acute extrapyramidal side effects in comparison with haloperidol. Some methodological flaws in the experimental design of the clinical trials analysed are discussed. Although these novel AP drugs have potential clinical advantages, a number of relevant questions still remain to be addressed, in order to establish the impact of these drugs in the overall treatment of schizophrenia. Copyright 2000 John Wiley & Sons, Ltd.